Investigational drug · Phase 2
lufepirsen
Also called: NEXAGON
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Persistent Corneal Epithelial Defect.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "lufepirsen"
First trial start
2023
Aug 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "lufepirsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Persistent Corneal Epithelial Defect
Largest trials
Live from ClinicalTrials.gov: studies naming "lufepirsen" as an intervention, largest first.
Glaukos CorporationIndustry
NCT05966493 · 84 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 2025
Drug: lufepirsen high dose; Vehicle and 1 more · For: Persistent Corneal Epithelial Defect
Sites: Dothan, Alabama; Petaluma, California; Torrance, California · 28 sites in all
- NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular InjuriesTerminated
Glaukos CorporationIndustry
NCT04081103 · 35 participants · Start Jun 30, 2020 · Primary completion Feb 7, 2022
Drug: Nexagon® (lufepirsen) High Dose Concentration; Nexagon® (lufepirsen) Low Dose Concentration and 2 more · For: Corneal Persistent Epithelial Defect
Sites: Los Angeles, California
Newest research
PubMed records naming it or its code names, newest first.
- Emerging Treatments for Persistent Corneal Epithelial Defects.
Kwon JE, Kang C, Moghtader A, et al. · Vision (Basel) 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.